At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1 enrolled
Drug / intervention
Dabrafenib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
In Brief
A Phase 2 clinical trial evaluating Dabrafenib and Trametinib for Ameloblastoma and BRAF Gene Mutation. Completed, enrolled 1 participant across 1 site.
Detailed Summary
This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmeloblastoma, BRAF Gene Mutation
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartJul 2017
Primary CompletionNov 2018
Study CompletionJun 2019
TodayJul 2026
First PostedFeb 20, 2015
Enrollment StartJul 17, 2017
Primary CompletionNov 5, 2018
Study CompletionJun 26, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.4 years ago
Interventions
Dabrafenibdrug
Given PO
Trametinibdrug
Given PO